CARTESIAN THERAPEUTICS INC.
NASDAQ: RNAC (Cartesian Therapeutics, Inc.)
Last update: 13 hours ago19.02
-0.25 (-1.30%)
| Previous Close | 19.27 |
| Open | 18.96 |
| Volume | 694,988 |
| Avg. Volume (3M) | 132,096 |
| Market Cap | 483,391,424 |
| Price / Sales | 1.97 |
| Price / Book | 642.47 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2025 - 10 Mar 2025 |
| Operating Margin (TTM) | -4,541.34% |
| Diluted EPS (TTM) | -55.43 |
| Quarterly Revenue Growth (YOY) | -94.10% |
| Total Debt/Equity (MRQ) | 1,948.27% |
| Current Ratio (MRQ) | 10.70 |
| Operating Cash Flow (TTM) | -39.96 M |
| Levered Free Cash Flow (TTM) | -2.93 M |
| Return on Assets (TTM) | -10.95% |
| Return on Equity (TTM) | -7,029.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cartesian Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.40 |
|
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 61.39% |
| % Held by Institutions | 27.85% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Bioimpact Llc | 30 Sep 2024 | 629,423 |
| Great Point Partners I Lp | 30 Sep 2024 | 200,000 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 173,566 |
| Yale University | 30 Sep 2024 | 100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (HC Wainwright & Co., 136.59%) | Buy |
| Median | 42.00 (120.82%) | |
| Low | 41.00 (Needham, 115.56%) | Buy |
| Average | 42.67 (124.34%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 20.45 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 19 Dec 2024 | 42.00 (120.82%) | Buy | 19.27 |
| HC Wainwright & Co. | 04 Dec 2024 | 45.00 (136.59%) | Buy | 22.00 |
| 08 Nov 2024 | 41.00 (115.56%) | Buy | 20.76 | |
| Needham | 03 Dec 2024 | 41.00 (115.56%) | Buy | 20.08 |
| 25 Nov 2024 | 41.00 (115.56%) | Buy | 17.91 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KURTOGLU METIN | - | 23.62 | -13,664 | -329,112 |
| Aggregate Net Quantity | -13,664 | |||
| Aggregate Net Value ($) | -329,112 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 23.62 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KURTOGLU METIN | Officer | 10 Dec 2024 | Sell (-) | 2,901 | 22.81 | 66,172 |
| KURTOGLU METIN | Officer | 10 Dec 2024 | Option execute | 2,901 | - | - |
| KURTOGLU METIN | Officer | 09 Dec 2024 | Sell (-) | 10,763 | 24.43 | 262,940 |
| KURTOGLU METIN | Officer | 09 Dec 2024 | Option execute | 10,763 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |